Treatment of Anemia With Intravenous Iron in Patients Listed for Orthotopic Liver Transplantation

Treatment of Anemia With Intravenous Iron in Patients Listed for Orthotopic Liver Transplantation

The aim of this study is to investigate whether therapy with intravenous iron carboxymaltose in patients with iron deficiency anemia (IDA) listed for orthotopic liver transplantation (OLT) increases hemoglobin concentrations and reduces intraoperative transfusion of packed red blood cells (PRBCs). The investigators hypothesize that therapy with intravenous iron will increase hemoglobin concentrations and reduce intraoperative transfusion of PRBCs in patients with IDA listed for OLT.

Inclusion Criteria:

• patients listed for OLT with positive screening for IDA

Exclusion Criteria:

• Age <18 years
• Hemochromatosis
• Iron utilization disorders
• Non-IDA
• Therapy with erythropoietin-stimulating agents or intravenous iron within 4 weeks prior to screening
• Previous allergic reactions against intravenous iron formulations
• Transfusion within 2 weeks prior to screening
• Complete portal vein thrombosis
• High-urgency OLT
• Pregnancy
• Sepsis or severe infection
• Immunosuppressive therapy